Lee Seungjae, Lee Sangmi, Desnick Robert, Yasuda Makiko, Lai Eric C
Developmental Biology Program, Sloan Kettering Institute, New York, NY, USA.
Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Science. 2024 Dec 20;386(6728):1427-1434. doi: 10.1126/science.adp9388. Epub 2024 Dec 19.
microRNAs (miRNAs) and small interfering RNAs (siRNAs) are 21- to 22-nucleotide RNAs that guide Argonaute-class effectors to targets for repression. In this work, we uncover 5-aminolevulinic acid synthase 1 (ALAS1), the initiating enzyme for heme biosynthesis, as a general repressor of miRNA accumulation. Although heme is known to be a positive cofactor for the nuclear miRNA processing machinery, ALAS1-but not other heme biosynthesis enzymes-limits the assembly and activity of Argonaute complexes under heme-replete conditions. This involves a cytoplasmic role for ALAS1, previously considered inactive outside of mitochondria. Moreover, conditional depletion of ALAS activity from mouse hepatocytes increases miRNAs and enhances siRNA-mediated knockdown. Notably, because is the target of a Food and Drug Administration-approved siRNA drug, agents that suppress ALAS may serve as adjuvants for siRNA therapies.
微小RNA(miRNA)和小干扰RNA(siRNA)是21至22个核苷酸的RNA,它们引导AGO类效应蛋白作用于靶标以实现抑制作用。在本研究中,我们发现血红素生物合成的起始酶5-氨基乙酰丙酸合酶1(ALAS1)是miRNA积累的一般抑制因子。尽管已知血红素是核miRNA加工机制的正性辅助因子,但在血红素充足的条件下,只有ALAS1(而非其他血红素生物合成酶)会限制AGO复合物的组装和活性。这涉及到ALAS1在细胞质中的作用,此前认为它在线粒体之外没有活性。此外,从小鼠肝细胞中条件性去除ALAS活性会增加miRNA并增强siRNA介导的基因敲低。值得注意的是,由于[具体药物名称未给出]是美国食品药品监督管理局批准的一种siRNA药物的靶标,抑制ALAS的药物可能用作siRNA疗法的佐剂。